دورية أكاديمية
Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
| العنوان: | Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV |
|---|---|
| المؤلفون: | De Matteis,Serena, Ghetti,Martina, Gramantieri,Laura, Marisi,Giorgia, Casadei-Gardini,Andrea |
| بيانات النشر: | Dove Press |
| سنة النشر: | 2021 |
| المجموعة: | Dove Medical Press |
| مصطلحات موضوعية: | OncoTargets and Therapy |
| الوصف: | Serena De Matteis,1 Martina Ghetti,2 Laura Gramantieri,3 Giorgia Marisi,2,* Andrea Casadei-Gardini4,* 1Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy; 2Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadoriâ€, Meldola (FC), Italy; 3Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy; 4Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy*These authors contributed equally to this workCorrespondence: Martina GhettiBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadoriâ€, via Piero Maroncelli 40, Meldola (FC), 47014, ItalyTel/Fax +39-0543-739977Email martina.ghetti@irst.emr.itAbstract: Hepatitis B- and C-virus (HBV and HCV) infections contribute to hepatocellular carcinoma (HCC) development through several different mechanisms. In addition to a diverse molecular background, HCC subtypes also show differences in their metabolic profiles, suggesting that prevention and treatment might require the integration of multiple different approaches. We here analyzed the response of two HCC cell lines representative of different virus-related etiology, namely Hep3B (HBV+) and HUH7 (permissive to HCV replication) to sorafenib treatment. Our findings suggest that virus-related specificities influence treatment response in HCC, along with molecular, metabolic and microenvironmental factors. These differences have to be taken into account in the design of future clinical trial aimed to improve HCC patients’ outcome.Keywords: hepatocellular carcinoma, hepatitis virus, kinase inhibitor |
| نوع الوثيقة: | article in journal/newspaper report |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/sorafenib-in-the-treatment-of-virus-related-hcc-differences-between-hc-peer-reviewed-fulltext-article-OTTTest |
| الإتاحة: | https://doi.org/10.2147/OTT.S312748Test https://www.dovepress.com/sorafenib-in-the-treatment-of-virus-related-hcc-differences-between-hc-peer-reviewed-fulltext-article-OTTTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.4E9C1CCB |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |